MONTPELLIER, France, May 11, 2016 (GLOBE NEWSWIRE) — MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, today announced that 100 spinal surgeries have successfully been performed with ROSA™ Spine, its robotic-assistive device for minimally-invasive surgery of the spine.
Surgeries utilizing ROSA Spine have been performed by:
- Dr. Michel Lefranc, a neurosurgeon at Amiens-Picardy University Hospital (France),
- Prof. Michael Winking at Klinikum Osnarbrück (Germany),
- Dr. Juan Torres-Reveron at Miami Valley Hospital in Dayton, Ohio (United States),
- Dr. Carlos Botella at Hospital La Fe à Valencia (Spain).
The 100th case was performed by Dr. Michel Lefranc. “Having performed several procedures with ROSA™ Spine, I have been extremely pleased with its accuracy and versatility,” said Dr. Lefranc. “The assistance of the robot allows the surgeon to perform the surgery as it was previously planned.”
ROSA™ Spine received the CE Mark in 2014 and was granted FDA clearance in the U.S. in January 2016.
“The 100th ROSA™ Spine procedure is a significant milestone for our Company that only scratches the surface of the potential opportunities for our ROSA robotic surgery system,” said Bertin Nahum, CEO and founder of Medtech. “This achievement continues to further validate our technology as an innovative approach in the spine market.”
To view the new Medtech corporate film, click here.
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT: CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 firstname.lastname@example.org PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 email@example.com Joanna Zimmerman (US) Tel : +1 646-536-7006 firstname.lastname@example.org